Section Arrow
Quote
MNPR.NASDAQ
- Monopar Therapeutics Inc
Quotes are at least 15-min delayed:2026/08/31 16:46 EDT
After Hours
Last
 111.93
0 (0.00%)
Bid
76.77
Ask
178.6
High 111.93 
Low 111.93 
Volume 1.19K 
Regular Hours (Closed)
Last
 111.93
+0.04 (+0.04%)
Day High 
112.965 
Prev. Close
111.89 
1-M High
124.82 
Volume 
140.75K 
Bid
76.77
Ask
178.6
Day Low
106.67 
Open
110.7 
1-M Low
104.48 
Market Cap 
751.02M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 113.97 
20-SMA 114.88 
50-SMA 105.83 
52-W High 124.82 
52-W Low 32.77 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.20/-1.46
Enterprise Value
751.18M
Balance Sheet
Book Value Per Share
19.50
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
CLGNCollPlant Biotechnologies Ltd0.3879+0.0299+8.35%-- 
After Hours 0.362356 -0.025544 -6.59%
AIMAIM ImmunoTech Inc.0.226-0.0324-12.54%-- 
After Hours 0.2447 +0.0187 +8.27%
ROIVRoivant Sciences Ltd34.64-0.07-0.20%-- 
After Hours 34.45 -0.19 -0.55%
CVKDCadrenal Therapeutics Inc1.75+0.21+13.64%-- 
After Hours 1.69 -0.06 -3.43%
MRNAModerna140.34+2.35+1.70%-- 
After Hours 139.4 -0.94 -0.67%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.